ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,099.96
1.02%
US Tech 100
17,244.80
1.57%
다우존스 지수
38,239.66
0.40%
Bitcoin
62,885.68
-1.33%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Altimmune Inc (ALT)

  7. Altimmune Inc (ALT) 뉴스

ALT Altimmune Inc

7.20
0.00 (0.00%)
27 4월(4) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
Altimmune Inc ALT 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
Upgrade Icon
0.00 0.00% 7.20 07:15:55
개장가 저가 고가 종가 전일 종가
7.18 6.90 7.42 7.26 7.20
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
26/04/202406:24GLOBEAltimmune Statement on the Passing of Dr. Stephen Harrison
27/03/202420:00GLOBEAltimmune Announces Positive Lean Mass Preservation Data for..
27/03/202419:57IHMARKETNEWSU.S. Stock Index Futures Point to a Rebound, Oil See..
20/03/202420:30GLOBEAltimmune to Report Fourth Quarter and Full Year 2023..
15/02/202402:04EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/02/202420:37EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/02/202408:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/02/202408:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/02/202408:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/02/202408:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/02/202408:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/02/202408:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/02/202408:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/02/202408:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/01/202408:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/01/202408:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/01/202408:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/01/202408:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/01/202408:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/01/202401:49EDGAR2Form SC 13G - Statement of acquisition of beneficial..
05/01/202408:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/01/202408:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/01/202421:30GLOBEAltimmune Announces Presentation of Pemvidutide Clinical..
08/12/202322:35GLOBEWater Tower Research US Climate Virtual Investor Conference:..
04/12/202322:35GLOBEWater Tower Research US Climate Investor Conference Agenda..
01/12/202306:28EDGAR2Form 8-K - Current report
01/12/202306:24GLOBEAltimmune Announces Positive Topline Results from MOMENTUM..
08/11/202306:08EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202321:06EDGAR2Form 8-K - Current report
07/11/202321:00GLOBEAltimmune Announces Third Quarter 2023 Financial Results and..
31/10/202320:30GLOBEAltimmune to Report Third Quarter 2023 Financial Results and..
26/10/202321:15DJNAltimmune Gets FDA Fast-Track Designation for Pemvidutide in..
26/10/202320:30GLOBEAltimmune Granted Fast Track Designation by FDA for..
25/10/202320:30GLOBEAltimmune to Present New Data on the Anti-Inflammatory and..
17/10/202320:30GLOBEAltimmune to Participate at Two Upcoming Investor..
30/09/202306:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/09/202306:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/09/202306:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/09/202306:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/09/202306:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/09/202305:55EDGAR2Form 8-K - Current report
26/09/202320:30GLOBEAltimmune Announces Oral Presentation of Pemvidutide..
12/09/202320:30GLOBEAltimmune Announces Completion of Dosing in the Phase 2..
30/08/202320:30GLOBEAltimmune to Participate at Two Upcoming Investor..
17/08/202305:14EDGAR2Form ARS - Annual Report to Security Holders
17/08/202305:10EDGAR2Form DEF 14A - Other definitive proxy statements
16/08/202307:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/08/202305:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/08/202320:04EDGAR2Form 8-K - Current report
10/08/202320:00GLOBEAltimmune Announces Second Quarter 2023 Financial Results..

최근 히스토리

NASDAQ
ALT
Altimmune
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유